COR2ED The Heart of Medical Education
Our COR2ED channel brings together world-renowned medical experts to discuss and provide clear guidance on the latest scientific and clinical insights in various therapeutic areas, including oncology, cardiology, hemostasis, rare diseases, hemato-oncology, and endocrinology. At COR2ED, we are committed to providing balanced and evidence-based independent medical education to support healthcare ...
read more ↘
read more ↘
Treating ER+/HER2-Low mBC: 2L and Beyond
By
COR2ED The Heart of Medical Education
FEATURING
Aditya Bardia
By
COR2ED The Heart of Medical Education
FEATURING
Aditya Bardia
Journey through a patient case from testing and diagnosis to treatment and AE management.
In this on-demand Tweetorial video from BREAST CANCER CONNECT, esteemed expert Dr Aditya Bardia presents a patient with ER+/HER2-low metastatic breast cancer, exploring the entire diagnostic and treatment process.
Dr Aditya Bardia discusses:
- Elacestrant improves PFS vs SOC in patients with ESR1m, irrespective of PIK3CAm or HER2-low status
- Hyperglycemia is a target side effect of the PIK3CA inhibitors and needs to be monitored closely
- T-DXd can be considered for patients with HER2-low mBC after ≥1 line of ChT
Visit our website to get the key clinical takeaways and find out more about our featured expert.
The medical experts in this video are expressing their own views and not those of COR2ED, supporters, or their institution. This programme is supported by an Independent Medical Education Grant from Menarini Stemline Oncology.
This video is developed by cor2ed.com
In this on-demand Tweetorial video from BREAST CANCER CONNECT, esteemed expert Dr Aditya Bardia presents a patient with ER+/HER2-low metastatic breast cancer, exploring the entire diagnostic and treatment process.
Dr Aditya Bardia discusses:
- Elacestrant improves PFS vs SOC in patients with ESR1m, irrespective of PIK3CAm or HER2-low status
- Hyperglycemia is a target side effect of the PIK3CA inhibitors and needs to be monitored closely
- T-DXd can be considered for patients with HER2-low mBC after ≥1 line of ChT
Visit our website to get the key clinical takeaways and find out more about our featured expert.
The medical experts in this video are expressing their own views and not those of COR2ED, supporters, or their institution. This programme is supported by an Independent Medical Education Grant from Menarini Stemline Oncology.
This video is developed by cor2ed.com
Comments 0
Login to view comments.
Click here to Login
